Intra Dialytic Hypotension - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 30

Intra Dialytic Hypotension – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Intra Dialytic Hypotension - Pipeline Review, H2 2012', provides an overview of the Intra Dialytic Hypotension therapeutic pipeline. This report provides information on the therapeutic development for Intra Dialytic Hypotension , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intra Dialytic Hypotension . 'Intra Dialytic Hypotension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Intra Dialytic Hypotension .
- A review of the Intra Dialytic Hypotension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Intra Dialytic Hypotension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Intra Dialytic Hypotension .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Intra Dialytic Hypotension pipeline depth and focus of Intra Dialytic Hypotension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Intra Dialytic Hypotension Therapeutic Products under Development, Key Players in Intra Dialytic Hypotension Therapeutics, Intra Dialytic Hypotension Pipeline Overview, Intra Dialytic Hypotension Pipeline, Intra Dialytic Hypotension Pipeline Assessment

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Intra Dialytic Hypotension Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Intra Dialytic Hypotension 6
Intra Dialytic Hypotension Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Intra Dialytic Hypotension Therapeutics – Products under Development by Companies 10
Companies Involved in Intra Dialytic Hypotension Therapeutics Development 11
Medinox, Inc. 11
Chelsea Therapeutics, Inc. 12
Intra Dialytic Hypotension – Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
Northera - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Norathiol - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Intra Dialytic Hypotension Therapeutics – Drug Profile Updates 22
Intra Dialytic Hypotension Therapeutics - Dormant Products 27
Intra Dialytic Hypotension – Product Development Milestones 28
Featured News & Press Releases 28
Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension 28
Jan 07, 2007: Chelsea Therapeutics Initiates Phase II Study Of Droxidopa In Intradialytic Hypotension 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
Number of Products Under Development for Intra Dialytic Hypotension, H2 2012 6
Products under Development for Intra Dialytic Hypotension – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Comparative Analysis by Mid Clinical Stage Development, H2 2012 9
Products under Development by Companies, H2 2012 10
Medinox, Inc., H2 2012 11
Chelsea Therapeutics, Inc., H2 2012 12
Assessment by Monotherapy Products, H2 2012 13
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Stage and Molecule Type, H2 2012 17
Intra Dialytic Hypotension Therapeutics – Drug Profile Updates 22
Intra Dialytic Hypotension Therapeutics – Dormant Products 27

List of Figures
Number of Products under Development for Intra Dialytic Hypotension, H2 2012 6
Products under Development for Intra Dialytic Hypotension – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Mid Clinical Stage Products, H2 2012 9
Assessment by Monotherapy Products, H2 2012 13
Assessment by Route of Administration, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Molecule Type, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 17

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Alzheimer's Disease - Pipeline Review, H2 2012
• Schizophrenia - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Insomnia - Pipeline Review, H2 2012